宫颈癌放化疗联合MRI引导近距离放疗后淋巴结失败模式:EMBRACE研究队列分析
EMBRACE国际多中心研究分析1338例宫颈癌患者,接受放化疗和MRI引导近距离放疗,中位随访34个月,总体淋巴结失败率11%,N-与N+分别为7%和16%;41%的淋巴结失败位于 elective 靶区外,其中39%在腹主动脉旁区域。
要点
- 总体淋巴结失败率低(11%),N-患者显著低于N+患者(7% vs 16%)。
- 诊断时病理淋巴结主要位于盆腔,但淋巴结失败更常见于腹主动脉旁区域。
- 约40%的淋巴结失败位于治疗靶区外,提示靶区覆盖需关注。
核心结论
- EMBRACE队列中淋巴结失败总体发生率低,N-患者显著低于N+患者。
- 诊断时病理淋巴结主要位于盆腔,而淋巴结失败更常报告于腹主动脉旁区域。
- 约40%的淋巴结失败位于治疗靶区外,其中39%在腹主动脉旁区域。
研究设计与样本
- 国际多中心EMBRACE研究队列分析,纳入1338例宫颈癌患者。
- 治疗为放化疗联合MRI引导近距离放疗,腹主动脉旁放疗和/或淋巴结推量由治疗中心决定。
- 按区域(盆腔、腹股沟、腹主动脉旁)分析诊断时淋巴结状态和淋巴结失败。
主要发现
- 中位随访34个月,83%的淋巴结失败发生在24个月内。
- 诊断时52%的患者有病理淋巴结,N+患者中99%位于盆腔、14%位于腹主动脉旁。
- 淋巴结失败患者中,盆腔失败占55%,腹主动脉旁失败占68%。
- 总体淋巴结失败152例(11%),N-和N+分别为7%和16%。
临床怎么用
- 宫颈癌放化疗联合MRI引导近距离放疗后淋巴结失败率低,但需关注腹主动脉旁区域和靶区外失败。
- N+患者淋巴结失败风险较高,应优化靶区覆盖和随访策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE/OBJECTIVE(S): To investigate the patterns of nodal failure in patients enrolled in the international multicentre EMBRACE study. MATERIALS/METHODS: Nodal disease at diagnosis (N-, N+) and nodal failure were analysed per region (NF) (pelvic (parametrial, common iliac, internal/external iliac), inguinal and para-aortic (PAO)) in 1338 patients. Treatment consisted of chemo-radiation and MRI guided brachytherapy. PAO radiotherapy and/or nodal boost was left to the treating centre. At time of diagnosis 52% of patients had pathologic nodes. Frequency analyses were performed in relation to patient, primary tumour and nodal disease characteristics, and treatment related factors. RESULTS: Median follow up was 34 months and 83% of NF occurred within 24 months. At diagnosis 99% of the N+ patients had pathologic nodes in the pelvis and 14% in the PAO. NFpelvic and NFPAO were reported in 55% and 68% of patients with NF, respectively. Overall NF was reported in 152 patients (11%); 7 and 16% for N- and N+ patients. Of the patients with NF, 41% were located outside the elective target (39% PAO), 40% inside and 35% inside the nodal boost target. Twelve percent of N+ patients that received a nodal boost had a NF inside the nodal boost target. CONCLUSION: Within the EMBRACE study cohort the overall number of patients developing nodal failure is low, significantly lower for N- compared to N+ patients. Pathological nodes at diagnosis are mainly located in the pelvis, whereas nodal failures are more often reported in the PAO region. About 40% of all nodal failures were reported outside the treatment targets.
引用
- Nomden CN, Pötter R, de Leeuw AAC, et al. Nodal failure after chemo-radiation and MRI guided brachytherapy in cervical cancer: Patterns of failure in the EMBRACE study cohort. Radiother Oncol. 2019. PMID: 31005214. doi:10.1016/j.radonc.2019.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。